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Summary and Key Points 
1. Chronic cancer pain is usually managed with multimodal analgesia, 
the combination of opioids, Cyclooxygenase (COX) inhibitors, 
anticonvulsants, and/or antidepressants. 
2. Opioids are excellent analgesics but are associated with significant 
toxicity. Ventilatory depression may be life-threatening, particularly in 
opioid-naïve subjects or those receiving concurrent benzodiazepines. 
Constipation is nearly universal and warrants pre-emptive therapy 
when opioids are initiated. 
3. COX inhibitors are also excellent analgesics. Gastrointestinal (GI) 
ulceration, and decreased platelet function are significant adverse 
effects of the nonselective and selective COX-1 inhibitors, but not the 
selective COX-2 inhibitors, which are associated with an increased 
risk of myocardial infarction. 
4. Anticonvulsants and/or antidepressants may be particularly useful in 
neuropathic pain. 
5. Glucocorticoids may relieve pain, either by decreasing swelling or by 
an adjuvant effect. 
6. Combination therapy with two or more classes of medications may 
decrease the doses of each required to achieve adequate pain relief. 
7. Radiation therapy is very effective local treatment for certain types of 
cancer pain, particularly bone pain, compression of nerves and 
Glissen’s capsule pain. 
8. Blocking neural transmission by injection of local anesthetics or 
neurolytics can respectively, relieve pain temporarily or long-term 
(months). 
9. Transcutaneous electrical nerve stimulators (TENS) units may be 
used as local therapy. 
10. Physical therapy or physical measures such as heat, cold or bracing, 
may relieve some pain. 
11. Cognitive behavioral therapy may make pain more bearable. 
12. Complementary or alternative therapies have a role for some patients. 
13. Pain is a part of the course of the disease for greater than half of 
cancer patients, roughly in proportion to stage of disease. But 
uncontrolled pain is the greatest fear of most patients and their 
families. 
14. Epidural or intrathecal administration of opioids, local anesthetics, and 
other agents can give relief in the setting of intractable pain or 
intolerable side effects of systemic opioids. 
Introduction 
Pain is one of the first concerns most cancer patients express when newly 
diagnosed or meeting a new physician. They are concerned about how 
much pain they presently have, how much pain they are likely to 
experience, and their physicians’ commitment to treating cancer pain. The 
reality is that many cancer patients will never experience pain during their 
course and for those that do, the great majority can be well-managed with 
the tools described in this chapter. It is incumbent on every physician to 
understand the mechanisms of cancer pain and the fundamentals of 
treating it. 
Cancer pain may be somatic (e.g., a pathological fracture of a long bone 
with a metastasis), visceral (e.g., a locally metastatic intra-abdominal 
tumor or neuropathic (e.g., spinal nerve root compression from a vertebral 
metastasis). It is important to attempt to identify the mechanism of cancer 
pain because neuropathic pain responds poorly to opioids and COX 
inhibitors. 
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There are four primary classes of analgesics given systemically to treat 
cancer pain: 
• opioids 
• COX inhibitors 
• anticonvulsants 
• antidepressants 
Different medications may be injected locally to block neural transmission 
to relieve pain, either temporarily (e.g., local anesthetics) or long-term 
(e.g., absolute ethanol). 
Analgesics may be administered for systemic effect by several different 
routes. The best route depends on the clinical situation. It is important to 
remember that time to maximal effect varies depending on the agent and 
on the route of administration. Most commonly, the oral route is used. If 
the oral route is not available (due to inability to swallow, loss of 
consciousness or other reasons), or if more rapid onset is desired, 
intramuscular injection (IM), buccal or sublingual or transanal (PA) routes 
may be used. If even more rapid onset of action is required, intravenous 
administration (IV) is used. Epidural or intrathecal administration of 
opioids, local anesthetics, and other agents can give relief in the setting of 
intractable pain or intolerable side effects of systemic opioids. Finally, 
fentanyl is available as a transdermal patch for long acting use. 
Opioids 
Opioids are used for many conditions. The opioids used in cancer pain are 
full agonists at the -opioid receptor. The mechanisms of analgesia 
involve modulating the transmission of pain impulses in the spinal cord 
and altering the perception of pain in the brain. Unlike local anesthetics 
that may render an area numb and insensate, opioids do not prevent the 
perception of pain but permit the patient to feel it as less noxious. 
In addition to analgesia, opioid agonists produce other characteristic dose-
dependent effects: 
• ventilatory depression 
• sedation 
• miosis (pupillary constriction) 
• constipation (by decreasing GI propulsive muscle activity and 
increasing GI sphincter activity) 
Tolerance develops when opioids are administered for chronic pain. This 
effect is manifested as a decrease in the duration and the intensity of the 
analgesic effect following a dose and requires increasing the opioid dose 
as the duration of therapy increases. Along with tolerance is the 
development of physical dependence, defined as the occurrence of a 
stereotypical withdrawal syndrome when drug administration is stopped 
abruptly or an antagonist is administered. It is important to differentiate 
tolerance and physical dependence from substance use disorder (formerly 
called addiction). While it is typical for persons with substance 
dependence who use opioids to develop tolerance and physical 
dependence, it is actually quite uncommon that persons appropriately 
prescribed opioids for pain develop new substance use disorder.1 
A recent study, based on the newly-released DSM-5 criteria for opioid-use 
disorder, revealed that the lifetime risk of moderate or severe opioid-use 
disorder among patients using opioids long-term for chronic (non-cancer) 
pain was only 13%.2 There is a significant genetic component to the risk 
of developing opioid use disorder. Persons with impulsivity and novelty-
seeking behavior types that may be in part genetically determined are at 
higher risk. Additional risk factors include those related to family, peer, and 
environmental factors. 
Several screening instruments are available to assess risk of substance 
use disorder. These include the Opioid Risk Tool (ORT), the Diagnosis, 
Intractability, Risk and Efficacy Inventory (DIRE), the Screener and Opioid 
Assessment for Patients with Pain (SOAPP), and the NIH-National 
Institute on Drug Abuse has a chart of Evidence-Based Screening Tools 
for Adults & Adolescents. One small study found that a semi-structured 
clinical interview combined with SOAPP were most effective at predicting 
risk at baseline in a group of patients who were discontinued from opioid 
medication for drug related issues.3 
Patients have often undertreated their pain with opioids because of the 
severity of the associated constipation. The new peripheral opioid 
antagonists, methylnaltrexone and naloxegol, are opioid receptor 
antagonists that do not penetrate the central nervous system. As a result, 
they do not interfere with the analgesic properties of opioids. However, by 
blocking the effects of opioids on the gut, they treat or prevent opioid-
induced constipation. These novel agents are useful when the traditional 
daily laxative regimen is ineffective. 
The primary difference between the opioids is their kinetics of onset and 
duration. The most common opioids are discussed below and summarized 
in Table 1. 
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Table 1. Dose, Time to Peak Effect, and Duration of Analgesia for 
Opioid Agonists 
Opioid Dose 
(mg)a 
Peak 
(min) 
Duration (h) 
Morphine (IV*) 10 >30 3-4 
Morphine (PO**) 40 60-120 3-6 
Codeine (PO) 60b 60-120 3-6 
Oxycodone (PO) 20 60-120 3-6 
Hydromorphone (PO) 6 60-120 3-6 
Methadone (PO) 10 120-180 (see text)c 
Fentanyl (transbuccal) 0.15 35-45 4-5 
aApproximately equianalgesic dose 
b See paragraph below on codeine. 
cThe initial dose of methadone lasts about 3-6 h.  As steady-state is approached 
after several days of therapy, a duration of 12-24 h can be expected. 
Morphine 
Morphine is the prototypical opioid to which all others are compared. It has 
a relatively slow onset, even after injection, and long duration. It has 
relatively low oral bioavailability (about 25%), and one of its metabolites, 
morphine-6-glucuronide, is active. Morphine is unique in that it commonly 
causes histamine release, an anaphylactoid reaction that may be 
manifested as flushing or itching. This is not an allergic reaction and in fact 
true allergy to morphine is unknown. Morphine is available both as an 
immediate release medication and as long-acting, sustained-release 
formulations. 
Codeine 
Codeine is a prodrug that requires conversion to morphine via CYP2D6. 
As mentioned in the footnote to Table 1, there is great interindividual 
heterogeneity in the expression of this isozyme. There is significant 
interindividual variability of the CYP2D6 phenotype with specific drug 
metabolism depending on the genotypic variation of the allele. About 10% 
of persons of western European descent lack CYP2D6 function and do not 
obtain analgesia from codeine, while some persons of middle-eastern 
descent have extra copies of CYP2D6 and may experience opioid toxicity 
from the usual doses of codeine. This property can cause significant risk 
to some patients with their first-ever dose of codeine, particularly children. 
Codeine is most commonly taken as a fixed-dose preparation that also 
contains acetaminophen. All acetaminophen-containing opioid products 
should be avoided in chronic pain patients because as the opioid dose is 
increased, a toxic dose of acetaminophen (> 4 g/d) is likely to be achieved. 
Persons with underlying liver disease or who drink ethanol may suffer liver 
damage at a lower daily dose of acetaminophen. 
Oxycodone 
Oxycodone has higher oral bioavailability than morphine and a more rapid 
onset. It is available alone or in combination with acetaminophen. Alone it 
is available as a conventional (i.e., immediate-release) formulation as well 
as a long-acting sustained-release preparation. 
Hydromorphone 
Hydromorphone is about sevenfold more potent than morphine-based IV 
dosing, about thirteenfold more potent than morphine-based PO dosing, 
and it does not cause histamine release as is sometimes seen with IV 
morphine. 
Methadone 
Methadone is inherently long-acting and does not require a sustained-
release formulation to be effective in once- or twice-daily dosing. It 
therefore takes days to reach steady-state and dosing changes should 
generally not be made more often than weekly. It is an excellent choice for 
patients with chronic pain and is inexpensive compared to other opioids. 
Methadone has also been associated with greater risk of a specific cardiac 
arrhythmia (torsades de pointes) that may prove fatal. Because 
methadone is also an antagonist at NMDA receptors, it is more effective 
against neuropathic pain than other opioids. 
Fentanyl 
Fentanyl is a highly potent, lipophilic opioid that is commonly used by IV 
route during anesthesia or for noxious procedures. It has both very rapid 
onset and offset by the IV route, however it has low oral bioavailability. It 
is commonly used in chronic pain, both as a patch and as a buccal tablet. 
The fentanyl patch is designed to be applied every three days and it is 
prescribed as the amount of fentanyl absorbed in mcg/hr. In general, it 
should only be used in persons tolerant to opioids. The fentanyl buccal 
tablet releases the drug for absorption directly through the buccal mucosa 
resulting in a rapid onset of effect. It is commonly used for breakthrough 
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pain in patients also using a fentanyl patch or some other long-acting 
opioid preparation. 
A person with severe cancer pain is generally given a long-acting 
medication to be taken on schedule as prescribed by their physician (by 
the clock), and in addition given a rapid-onset, short-duration medication 
as needed for breakthrough pain (the occurrence of a short-lived but 
intense increase in pain above and beyond the background of chronic 
pain, often brought on by a specific activity). 
It is helpful for patients to keep a log of their breakthrough medication 
usage and a rating of pain severity when the medication was taken. This 
information can be used to adjust the long-acting medication dosage, and 
may reveal that the patient is developing tolerance to the long-acting 
medication. The patient may then need an increase in dose and/or a 
decrease in dosing interval of the long-acting medication. Switching to a 
different opioid (“opioid rotation”) may restore, fully or partially, the 
analgesic effect. 
Severe or intractable cancer pain often results in very high doses of 
opioids used, for example a daily oral morphine total of 400 mg or more 
(or the equianalgsic amount of a similar agent.) At these doses, patients 
often have intolerable somnolence and sedation that can be reduced with 
the addition of a psychostimulant, such as methylphenidate. In addition, 
patients taking such high doses can develop neuro-excitatory side effects 
due to dose-dependent agonism of the N-methyl-D-aspartate (NMDA) 
receptor leading to myoclonus, allodynia (abnormal painful sensation to 
usual stimuli), and hyperalgesia (heightened pain sensation despite opioid 
use). Neuroexcitatory side effects call for a reduction in total opioid use, or 
rotation to a different opioid. 
An additional strategy for intolerable opioid side effects or ineffective pain 
relief is to deliver analgesic agents to the spinal cord and nerve roots by 
an epidural or intrathecal catheter connected to a temporary or implantable 
pump. Drug delivery can be regionalized to certain segments of the 
neuraxis and a combination of agents can be effective such as opioids, 
local anesthetics, and both sympathetic and para-sympathetic agents. 
Neuraxial medication delivery can allow much lower overall doses, 
reducing systemic side effects; there are unique complications of these 
interventions including infection and neurologic deficits. 
A person with cancer pain is also often given other medications to 
potentiate the opioid effect and/or decrease the needed dose of opioid. 
These medication classes are discussed below and this approach is called 
multimodal analgesia. 
COX Inhibitors 
Cox Inhibitor medications inhibit the isozymes of cyclooxygenase (COX) 
that catalyze the biosynthesis of prostaglandins. These agents were 
previously (and still in common parlance) erroneously called NonSteroidal 
Anti-Inflammatory Drugs, or NSAIDs. The desirable properties of many 
“NSAID’s” are due to profound antinociceptive, and not primarily anti-
inflammatory, effects (most notably ketorolac), but the anti-inflammatory 
effect may potentiate analgesia as well. 
There are two isozymes of COX, COX-1 and COX-2. COX-1 is a 
constitutive enzyme; its most important roles include the mediation of pain, 
stimulation of platelet adhesion, maintenance of renal blood flow, and 
protection of the GI mucosa. COX-1 inhibition has an anti-nociceptive 
effect. COX-2 is an inducible enzyme whose most important roles include 
the mediation of inflammation and the synthesis of an important 
endogenous vasodilator and anticoagulant (prostacyclin, or PGI2). COX-2 
inhibitors have anti-inflammatory effects. Some COX inhibitors are more 
specific for COX-1 or COX-2 while others are nonspecific (Table 2). The 
degree of inhibition of COX-1 is associated with the propensity for causing 
GI ulceration. Long term (greater than 12 months) use of COX-2 inhibitors 
is associated with an increased risk of cardiac ischemia and death. 
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Table 2. Characteristics of COX Inhibitors 
Drug Dosing Interval COX Inhibition 
Aspirin 4 h 1 > 2 
Acetaminophen 4 h‡ 1 = 2‡ 
Celecoxib 12 h 2 > 1 
Diclofenac 24 h* 2 > 1 
Diflunisal 12 h 1 = 2 
Etodolac 24 h* 2 > 1 
Ibuprofen 6 h 1 = 2 
Indomethacin 8 h* 1 >>2§ 
Ketorolac 6 – 8 h† 1 >> 2 
Naproxen 12 h 1 ≥ 2 
*Duration of the extended-release formulation 
†6 h for IV administration, 8 h for intramuscular (IM) administration 
‡At usual clinical concentrations, COX is inhibited only about 50%. Also, a 
metabolite of acetaminophen, N-acetyl-p-benzoquinone imine (NAPQI), is a 
hepatotoxin, which should limit total daily dose. 
§Has additional immunosuppressive actions beyond COX inhibition 
In cancer patients it is important to remember that acetaminophen is 
hepatotoxic in doses above about 4 g/d, and much less in children and 
patients with liver compromise due to tumor involvement, cachexia and 
malnutrition, cirrhosis, or history of alcohol use. 
Anticonvulsants 
While these medications do not typically act as analgesics in persons with 
nociceptive or inflammatory pain, they often relieve neuropathic pain and 
may potentiate opioid-induced analgesia. The most common 
anticonvulsants used for these purposes are gabapentin, pregabalin, and 
carbamazepine. 
Table 3.  Characteristics of Anticonvulsants 
Drug Dosing Interval 
Carbamazepine 12 h* 
Gabapentin 8 h 
Pregabalin 8 h 
*Duration of the extended-release formulation 
Carbamazepine has two important adverse effects that require careful 
attention: toxicity from elevated levels can lead to encephalopathy and 
ataxia, and rarely, carbamazepine can cause dangerous agranulocytosis. 
Antidepressants 
Antidepressants in the tricyclic class may also be used to treat neuropathic 
pain or to potentiate opioid effects. The most common antidepressant 
used in this way is amitriptyline. It is usually given once daily at bedtime. 
For patients with glaucoma or those unable to tolerate the side effects of 
amitriptyline, consider other tricyclics such as desipramine or nortriptyline 
that have fewer anticholinergic side-effects, or one of the newer serotonin-
norepinephrine reuptake inhibitors such as duloxetine or venlafaxine. 
Glucocorticoids 
Dexamethasone is used to treat or prevent edema, which sometimes will 
immediately relieve pain from nerve compression or intracranial pressure, 
by reducing vascular permeability, and inhibiting prostaglandin synthesis, 
decreasing inflammation. There is some direct reduction in inflammatory 
pain from the anti-inflammatory effect of these steroids. 
Dexamethasone and prednisone also have an important adjuvant function 
to other pain medications (as well as nausea medications), particularly for 
bone pain, neuropathic pain and visceral pain.4. 
Bone Stabilizing Agents 
Bone stabilizing agents such as bisphosphonates and denosumab are 
routinely used to prevent/postpone skeletal related events such as 
pathologic fractures in patients with known bone metastases, especially in 
breast cancer, thereby preventing the development of pain.5 High dose 
bisphosphonates have been shown to relieve bone pain in some patients 
with bony metastatic breast cancer.6 
Principles of Medication Pain Management 
Use of COX inhibitor medications prior to starting opioid therapy may 
decrease the opioid dose required to achieve adequate pain relief. In 
addition, use of two or more classes of medications will often decrease the 
total dose required of each medication. But the use of fixed dose tablets 
such as Tylenol #3® (acetaminophen + codeine) or Percocet® 
(acetaminophen + oxycodone) can be dangerous in cancer patients 
because patients will often attempt to achieve better pain control by self-
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escalating their doses to the point of acetaminophen toxicity. It is much 
safer to prescribe the two agents separately, and inform patients and 
caregivers how to increase both, and what the safe limit of each drug is. 
In general codeine should be avoided for cancer pain because of individual 
differences in activity of the enzyme, CYP2D6, which metabolizes it into 
its active metabolite, morphine. 
The World Health Organization (WHO) has published a “three-step ladder” 
approach to pain management, which suggests that pain management 
should start with non-opioid medication, with or without adjuvant 
medications, stepping up to “mild opioids” with or without adjuvants, 
including non-opioid analgesics, and finally a strong opioid, supplemented 
by the same adjuvant medications as Step 2. It is available here: 
http://www.who.int/cancer/palliative/painladder/en/ 
For children, the WHO has modified this to a two-step ladder, starting with 
a non-opioid analgesic, and progressing to the addition of morphine or 
other strong opioid, but this is controversial.7 Pediatric pain management 
is even more complicated than adult care. Here is a useful chart 
summarizing pediatric pain management principles: 
https://www.compassionandsupport.org/pdfs/professionals/pain/pain_pe
diatric_guide.pdf 
Pain management must be individualized for each patient and is not static. 
For example, opioids can cause unpleasant symptoms some of which are 
patient specific, and rotating to a different opioid may relieve those 
symptoms. Constipation is an opioid class effect, and must be managed 
prospectively with careful bowel regimens for every patient. Patients 
metabolize agents at different rates, and this may require variation from 
textbook scheduling. Escalating doses of strong opioids can actually 
exacerbate pain, referred to as opioid-induced hyperalgesia. Opioid-
induced hyperalgesia may respond to rotation to another opioid or 
decreasing the dose of the original medication.8 
Very severe pain unresponsive to normal management is called pain 
crisis; it is a medical emergency and requires the presence of a physician 
experienced in management of this crisis in constant attendance until a 
primary diagnosis is made and treatment initiated (e.g., pathological 
fracture, spinal cord compression or deep venous thrombosis), and/or pain 
relief is achieved.9 
Pain Relief from Radiation Therapy 
The mechanism of action of pain relief from radiation therapy has not been 
studied in depth, although it clearly works. Therefore, this section is based 
on speculation, and is intended to provide opportunities for research. 
Bone pain response varies from virtually immediately to very gradually, 
sometimes as much as two months after treatment. The almost 
instantaneous relief is probably due to a well-accepted anti-inflammatory 
effect; white cells are readily killed by low dose radiation. This effect used 
to be used regularly for pain of osteoarthritis, and clinical experience 
suggests that it was effective immediately in many patients. Patients’ pain 
sometimes responds a bit more gradually, over a few days to weeks, well 
before any radiographically visible bone healing or even visible change in 
tumor. This may be due to subtle tumor shrinkage, or an ill-defined 
hormonal response. Finally, pain may be relieved over six weeks- three 
months; this is consistent with bone healing after tumor cell death and 
resorption. Radiotherapy is a very effective therapy; one study 
demonstrated two-thirds of patients had pain relief and one-fourth were off 
opioids entirely.10 
A second, older study of 255 bone lesions in 205 patients with bone 
metastasis found complete pain relief in 62% and partial relief in an 
additional 14%. Prostate cancer metastases were most likely to respond; 
breast cancer lesions slightly less and nonsmall cell lung cancer lesions 
least likely to achieve complete pain relief. Complete relief and higher dose 
also lead to more durable response.11 
Bone seeking radiopharmaceuticals have been used for decades to treat 
pain from widely metastatic osteoblastic malignancy, most often prostate 
cancer. They work by seeking osteoblasts and any lesion that is evident 
on bone scan is likely to take up the isotope. Most of these agents have 
emitted beta particle, such as strontium-89 and samarium-153.12 Recently, 
radium-223, an alpha emitter, has been used, with randomized clinical trial 
evidence that it can also extend life expectancy.13 
It seems most likely that tumor shrinkage due to tumor cell kill is the 
mechanism of action for relief of pain due to nerve compression, Glisson’s 
capsule distension14 and obstruction of hollow visci.15 
Interventional Radiology 
Regional nerve blocks are usually done under radiologic guidance, usually 
ultrasonic or fluoroscopic, although they can be done as a dentist does, by 
detailed understanding of the neuroanatomy. 
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Local anesthetics can be used to temporarily block nerve transmission, 
either to prevent acute pain, or to treat a regional chronic pain syndrome.  
For example, long acting local anesthetic injected into an operative site 
before thoracotomy, in combination with adequate postoperative pain 
management, will often prevent the development of post thoracotomy 
pain, a severe chronic pain issue after chest surgery. Lumbar, brachial and 
celiac plexus blocks are effective means of treating regional pain. 
Table 4.  Characteristics of Local Anesthetics 
Drug Duration* 
Lidocaine 2-4 h 
Bupivacaine 12-24 h 
*Using epinephrine-containing solution. Duration will be at the longer end of the 
range with plexus block, and at the shorter end of the range with peripheral nerve 
block. 
If a local or regional block has been effective in relieving longstanding 
regional pain, consideration may be given to injection of a neurolytic agent 
to permanently ablate the nerve or ganglion transmitting the pain. 
Neurolytic ablation of the celiac plexus is particularly useful in treating the 
severe pain of inoperable pancreatic cancer. The two neurolytic agents 
used are 6% phenol and absolute (100%) ethanol. Phenol is a local 
anesthetic with a very prolonged (i.e., months) duration. While ethanol is 
more likely than phenol to result in permanent destruction of the nerve, its 
injection is initially quite painful, and requires the prior injection of a short-
acting local anesthetic (e.g., lidocaine) or that the alcohol injection is made 
with the patient under general anesthesia (as is commonly done with 
ultrasound-guided endoscopic celiac plexus ablation). Injecting a 1:1 
mixture of absolute alcohol and 1% lidocaine may reduce the pain of 
injection during celiac block. 
Pain from vertebral compression fractures may be treated with one of two 
forms of intervention, vertebroplasty, injection of medical cement into the 
damaged bone, or kyphoplasty, using a balloon to create a space in the 
bone which can then be filled with cement. 
Surgery 
Fractures at multiple adjacent vertebral levels may be treated with external 
fixation. Similarly, pathologic fractures of long bones will usually need 
surgical fixation to treat the pain of the fracture, followed by radiation 
therapy to prevent tumor progression and further fracture. 
Surgery may be also performed to relieve obstruction of hollow visci, but 
limited data on efficacy is available, and randomized controlled trials would 
be very difficult to perform.16 A limited number of other painful lesions may 
be most readily palliated with surgical resection. 
Topical Agents 
Some types of cancer pain involving the skin or relatively superficial 
structures (ribs, muscles, joints) can be treated by the local application of 
three agents as follows. For intact skin, lidocaine can be applied as a gel 
or cream with a relatively short duration of relief (10-30 minutes). A slow 
release lidocaine patch can provide up to 20 hours of relief for pain with a 
relatively superficial source. A mixture of lidocaine and prilocaine in a 
cream (EMLA) is commonly used in pediatric cancer patients before 
lumbar punctures and bone marrow aspiration biopsies to numb the skin, 
in combination with sedation. 
Subcutaneous tissues express opioid receptors, and topical morphine can 
be an effective salve for painful cancer-related wounds, particularly the 
inflammatory skin involvement typical seen in some breast cancers. Finally 
ketorolac gel is a product often used for osteoarthritic joint pain; it can be 
effective on intact skin for bone, muscle, and joint pain with reduced 
systemic side effects and pill burden. 
Non-Medical Treatments for Pain 
There are multiple types of non-medical treatments for pain that are 
available for patients. Patients are encouraged to talk with their health care 
providers when using these treatments. This section is not intended to be 
comprehensive; for more information, the American Cancer society has a 
list of non-medical treatments at: 
http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideef
fects/pain/non-medical-treatments-for-cancer-pain. 
Transcutaneous Electrical Nerve Stimulation (TENS) 
TENS treatment is said to be useful in the management of cancer pain, 
but a recent Cochrane review found the data for the use of this device to 
be equivocal. One study found some relief of bone pain on movement; 
another was negative.17 
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Physical Therapy 
Many patients will benefit from physical therapy, massage therapy and 
heat or cold therapy to treat regional areas of pain. 
Acupuncture or Acupressure 
Acupuncture or acupressure will relieve pain in some patients. It requires 
a trained, licensed acupuncturist to administer the acupuncture, but 
patients and caregivers can be trained to do acupressure, sometimes 
with a BB glued or taped to the critical spot. 
Psychotherapy 
Cognitive and behavioral therapy, meditation and mindfulness training will 
either relieve pain or make it more bearable for some patients. 
Alternative and Complementary Therapies 
Finally, complementary and alternative therapies may play a role in 
making patients feel better (see chapter). 
Conclusion 
Although pain is by no means part of the course of the disease for all 
cancer patients, it can be one of the greatest fears of newly diagnosed 
cancer patients and their families18. It is important to remember that 
modalities beyond medications are available, and that fatigue, depression 
and emotional/spiritual distress may exacerbate the experience of pain, 
requiring different or additional management. This chapter is focused on 
physical pain; existential pain, depression (whether reactive or 
longstanding) and spiritual pain are just as real but are largely beyond the 
scope of this chapter. 
Patients need to be aware that the goal may be to make pain bearable, 
rather than complete freedom from pain, especially if they wish to minimize 
side effects of pain medications. The use of the term “painkiller” should be 
discouraged for that reason. 
Management of pain in the cancer patient is complex, but every physician 
must have an understanding of the basics and be prepared to help with 
management and with reassuring patients that pain relief modalities will 
remain available to them throughout their experience of the disease. 
Thought Questions 
1. A 64 year old woman has been treated for metastatic breast cancer 
for the last three years. At the current time she has metastases in 
many bones, including ribs, spine, and both femurs. Plain films of the 
femurs do not suggest that she is at significant risk for fracture. 
However, she is having increasing pain in her back and chest wall. 
She was given oxycodone, but finds that she has persistent pain even 
after taking 10 mg every four hours. She has noted no drowsiness or 
constipation since starting oxycodone. In addition to discussing 
changes in anti-cancer therapy with her at her next visit, what changes 
to her pain treatment could you consider? 
Your answer: 
 
 
 
 
 
Expert Answer 
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2. Monday morning, a 60 year old man arrives at the oncology clinic from 
his primary care physician with a painful ulcer on the base of his 
tongue, complaining of pain he describes as 10 on the 0 to 10 pain 
scale, worse at times, especially when the pain wakens him from 
sleep. Friday afternoon, he was given a prescription for 
hydrocodone/acetaminophen 5/325, and is taking 2 tablets every 3 to 
4 hours, or 4 to 5 times per day, with some relief. He has a history of 
Hepatitis C, is currently smoking 2 packs per day, and describes past 
heavy alcohol use and current sobriety. What adjustments should be 
made to his analgesic regimen? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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3. A 57 year old man has been diagnosed with metastatic lung cancer. 
He describes severe back pain and has involvement of his vertebrae 
by metastases. He receives radiation to these areas but continues to 
have pain. When you meet with him for the first time you learn that he 
is divorced and lives by himself. No one has come with him to your 
appointment. He has adult children in the area that he sees a few 
times a year. He had been employed as an accountant, but has had 
to cut back his work because of his illness. He has a prescription for 
morphine (15 mg tablets) which he uses very rarely, because "I don't 
want to become addicted". In addition to suggesting treatment of his 
lung cancer, what other advice can you give him for pain control? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
4. Why is the use of the term “painkiller” unfortunate? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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Glossary 
-opioid receptor– The most important opioid receptor family for pain 
control 
Analgesics- Drugs used to provide pain relief 
Buccal- Relating to the cheek 
Cochrane review– Cochrane Reviews are internationally recognized 
systemic reviews considered to be the highest standard in evidence-
based health care and health policy. 
http://community.cochrane.org/cochrane-reviews 
Nociceptive pain– Pain from irritation of specialized nerve endings called 
nociceptors, which is seen in burns, for example. 
Neuropathic pain– Pain due to a malfunction from nerve injury– diabetic 
neuropathy for example 
Prodrug– A compound, which requires metabolism within the patient to 
become active. 
Torsades de pointes- A form of ventricular tachycardia, often seen with 
prolonged QT interval, in which the QRS complex has variable form, with 
the peaks pointing up and down, causing decreased blood pressure and 
sometimes syncope or near syncope. 
References 
1. Bruera E, Paice JA. Cancer Pain Management: Safe and Effective 
Use of Opioids. Am Soc Clin Oncol Educ Book. 2015; e593-9. 
2. Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among 
patients on long-term opioid therapy: impact of final DSM-5 diagnostic 
criteria on prevalence and correlates. Subst Abuse Rehabil. 2015; 
6:83-91. 
3. Moore TM, Jones T, Browder JH, Daffron S, Passik SD. A comparison 
of common screening methods for predicting aberrant drug-related 
behavior among patients receiving opioids for chronic pain 
management. Pain Med. 2009; 10(8):1426-33. 
4. Vyvey M. Steroids as pain relief adjuvants. Can Fam Physician. 2010; 
56(12): 1295-7. 
5. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone 
agents for breast cancer. Cochrane Database Syst Rev. 2012; 
2:CD003474. 
6. Diel IJ. Effectiveness of bisphosphonates on bone pain and quality of 
life in breast cancer patients with metastatic bone disease: a review. 
Support Care Cancer. 2007; 15(11):1243-9. 
PubMed Abstract 
7. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-
four years of experience. Can Fam Physician. 2010; 56(6): 514–7. 
8. Mercadante S, Ferrera P, Arcuri E, Casuccio A. Opioid-induced 
hyperalgesia after rapid titration with intravenous morphine: Switching 
and re-titration to intravenous methadone. Ann Palliat Med. 2012; 
1(1):10-3. 
9. Moryl N, Coyle N, Foley KM. Managing an acute pain crisis in a patient 
with advanced cancer: “this is as much of a crisis as a code”. JAMA. 
2008; 299(12):1457-67. 
PubMed Abstract 
10. Howell DD, James JL, Hartsell WF, et al. Single-fraction radiotherapy 
versus multifraction radiotherapy for palliation of painful vertebral bone 
metastases-equivalent efficacy, less toxicity, more convenient: a 
subset analysis of Radiation Therapy Oncology Group trial 97-14. 
Cancer. 2013; 119(4):888-96. 
11. Arcangeli G, Giovinazzo G, Saracino B, et al. Radiation therapy in 
the management of symptomatic bone metastases: the effect of total 
dose and histology on pain relief and response duration. Int J Radiat 
Oncol Biol Phys. 1998; 42(5):1119-26. 
PubMed Abstract 
12. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for 
the palliation of painful bone metastasis- a systemic review. Radiother 
Oncol. 2005; 75(3):258-70. 
PubMed Abstract 
13. Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med. 
2013; 369(17):1659-60. 
14. Sherman DM, Weichselbaum R, Order SE, et al. Palliation of hepatic 
metastasis. Cancer. 1978; 41(5):2013-7. 
Treatment of Cancer Pain 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (21 September 2016) 
12 
15. Picardi V, Deodato F, Guido A, et al. Palliative short-course radiation 
therapy in rectal cancer: A phase 2 study. Int J Radiat Oncol Biol. 
Phys. 2016; 95(4). 
PubMed Abstract 
16. Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of 
symptoms in malignant bowel obstruction in advanced gynaecological 
and gastrointestinal cancer. Cochrane Database Syst Rev. 2016; 
(1):CD002764. 
17. Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry 
SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain 
in adults. Cochrane Database Syst Rev. 2012; (3):CD006276. 
18. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, 
Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients 
with cancer: a systematic review of the past 40 years. Ann Oncol. 
2007; 18(9): 1437–49. 
 
